Evidence map›Paper›PMID 40470574›Full record

ArticleImmunotherapy2025

Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors.

Onur Bas, Mert Tokatlı, Naciye Guduk, Dilara Erdoğan, Nur Evşan Boyraz, Gözde Kavgaci, Taha Koray Sahin, Deniz Can Guven, Neyran Kertmen, Sercan Aksoy and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Onur BasDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.ORCID 0000-0002-8726-0360
Mert TokatlıDepartment of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Naciye GudukDepartment of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Dilara ErdoğanDepartment of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Nur Evşan BoyrazDepartment of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Gözde KavgaciDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Taha Koray SahinDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.ORCID 0000-0002-3590-0426
Deniz Can GuvenElazig City Hospital, Health Sciences University, Elazig, Turkey.
Neyran KertmenDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Sercan AksoyDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Mustafa ErmanDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Şuayib YalcinDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Ömer DizdarDivision of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlbumin and creatinine are considered important for understanding patient response to immune checkpoint inhibitors (ICIs). However, numerous confounding factors complicate the interpretation of albumin and creatinine alone in clinical practice. This study aims to assess the correlation between survival outcomes and serum-albumin creatinine ratio (sACR) in patients treated with ICIs.

methodsThis study was conducted on individuals who received at least three doses of ICI between 2018 and 2023. Patients were divided into two groups, sACR-High and sACR-Low, based on the median level. The relationship between sACR and survival outcomes was analyzed using a cox regression model. The relationship between sACR and early progression, late progression, and long-term benefit was analyzed using a logistic regression model.

resultsPatients with lower sACR had decreased overall survival (OS) (HR: 1.42, 95% CI 1.07-1.89,

conclusionsOur study demonstrated that sACR could serve as an independent predictor of OS, PFS, early progression, late progression, and long-term benefit in patients treated with ICIs.

Indexed as

Biomarkers, TumorCreatinineImmune Checkpoint InhibitorsNeoplasmsSerum AlbuminAdultAgedAged, 80 and overBiomarkersFemaleHumansMaleMiddle AgedPrognosisBiomarkersBiomarkers, TumorCreatinineImmune Checkpoint InhibitorsSerum AlbuminbiomarkerImmunotherapyprognosisserum-albumin creatinine ratiosurvival

Identifiers

PMID40470574
PMCPMC12218575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.